MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0400
+0.0200 (+1.96%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.0200
Open1.0300
Bid0.0000 x 900
Ask0.0000 x 3200
Day's Range1.0200 - 1.0400
52 Week Range0.7770 - 3.1500
Volume162,738
Avg. Volume204,050
Market Cap47.557M
Beta (3Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-0.3370
Earnings DateFeb 19, 2020 - Feb 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
  • PR Newswire

    Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from one of the Company's two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML").

  • PR Newswire

    Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

    Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 study HOUSTON , Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...

  • What Kind Of Shareholder Owns Most Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock?

    A look at the shareholders of Moleculin Biotech, Inc. (NASDAQ:MBRX) can tell us which group is most powerful. Insiders...

  • PR Newswire

    Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

    HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate, WP1122, which it believes may present a new approach to treating highly glycolytic tumors like pancreatic cancer and glioblastoma. "WP1122 represents an opportunity to attack the metabolism of cancer by exploiting the Warburg principle, which explains that some tumors are highly dependent on glycolysis, a specific metabolism of glucose, for growth and survival," commented Walter Klemp, Moleculin's Chairman and CEO.

  • PR Newswire

    Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that the FDA has approved a request for Investigational New Drug ("IND") status for its drug candidate WP1066 to be used in a Phase 1 clinical trial for the treatment of children with recurrent or refractory malignant brain tumors. The request was made by physician researchers at Emory University, including Dr. Tobey MacDonald, Professor of the Department of Pediatrics at Emory University School of Medicine, Director of Pediatric Neuro-Oncology at Aflac Cancer and Blood Disorders Center and Principle Investigator for this clinical trial.

  • PR Newswire

    Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the third quarter ended September 30, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, chairman and chief executive officer of Moleculin, said, "We are extremely pleased with the progress we have achieved year-to-date with our research programs and ongoing clinical trials setting the stage for the Company to report clinical results in the near future.

  • PR Newswire

    Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models

    HOUSTON, Oct. 29, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the presentation of a poster at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference today in Boston, MA. The poster, entitled "Dose and Schedule-Dependent Efficacy of Liposomal Annamycin in Pre-clinical Models of Acute Myeloid Leukemia," presents data documenting the high activity of Annamycin against AML, including in vitro studies in a panel of human AML cell lines, as well as in vivo studies in both human and murine AML models developed under the Company's sponsored research agreement with MD Anderson Cancer Center.

  • PR Newswire

    Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications

    HOUSTON, Oct. 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the expansion of Annamycin production commitments in response to management's assessment of positive AML clinical trial activity and the potential expansion of indications for use to include lung-localized tumors. The purchase commitment arranged through Davos Pharmaceuticals includes moving final production of Annamycin to a larger-scale suite within BSP Pharmaceuticals S.p.A. ("BSP") in Latina, Italy.

  • PR Newswire

    Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

    HOUSTON , Sept. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...

  • PR Newswire

    Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial

    HOUSTON, Aug. 20, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced approval by the Emory University Clinical Trial Review Committee (CTRC) to move forward with an Investigator Initiated clinical trial of Moleculin's immune-stimulating/transcriptional-modulator, WP1066, for the treatment of pediatric brain tumors. The trial will take place at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta.

  • PR Newswire

    Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

    HOUSTON, Aug. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, chairman and chief executive officer of Moleculin, said, "The second quarter of 2019 exhibited significant progress in the various research initiatives and clinical trials that are underway on our drug candidates.

  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • PR Newswire

    Moleculin Announces Completion of Lymphoma Trial Enrollment

    HOUSTON, Aug. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment. "We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," commented Walter Klemp, Moleculin's Chairman and CEO, "especially one that may avoid significant unwanted side effects.

  • PR Newswire

    Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

    HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a paper entitled "Immunological Reprogramming in the CNS Tumor Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade" will be presented at the Inaugural Conference on Brain Metastases, in New York City, August 16-17, 2019.

  • Benzinga

    Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

    Moleculin Biotech Inc (NASDAQ: MBRX) announced positive data Thursday from its Phase 1/2 study of annamycin in Poland. Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer. The company said intends to advance the clinical study of Annamycin to the next dose level.

  • PR Newswire

    Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

    HOUSTON, July 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. Three patients were treated at dose level of 150 mg/m2 with no drug-related adverse events, including no signs of cardiotoxicity.

  • Moleculin Files New Patents for Cancer Candidate Annamycin
    Zacks

    Moleculin Files New Patents for Cancer Candidate Annamycin

    Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

  • Benzinga

    Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection

    Moleculin Biotech Inc (NASDAQ: MBRX )'s stock was advancing Wednesday on heavy volume. Moleculin, which focuses on drugs targeting highly resistant tumors, said it has filed new patents covering the production ...

  • PR Newswire

    Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

    HOUSTON, July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).

  • What Type Of Shareholder Owns Moleculin Biotech, Inc.'s (NASDAQ:MBRX)?
    Simply Wall St.

    What Type Of Shareholder Owns Moleculin Biotech, Inc.'s (NASDAQ:MBRX)?

    If you want to know who really controls Moleculin Biotech, Inc. (NASDAQ:MBRX), then you'll have to look at the makeup...

  • PR Newswire

    Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

    HOUSTON, May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first quarter ended March 31, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. This time last year we had just commenced our first clinical trial for one drug.  Today, we have three drugs in four clinical trials under way with a fifth clinical trial that may start before year end.

  • PR Newswire

    Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe

    2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level HOUSTON , May 7, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...

  • PR Newswire

    Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has scheduled an investor conference call for May 15, 2019 with Joseph Moscato, President & Chief Executive Officer of Generex who will present an organizational roadmap outlining Generex Biotechnology's operational, strategic and financial plans, as outlined herein.

  • Positive Results From HMN Lithium Project P.E.A.
    CNW Group

    Positive Results From HMN Lithium Project P.E.A.

    Positive Results From HMN Lithium Project P.E.A.

  • PR Newswire

    US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

    Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (MBRX), recently recruited 3 patients in 6 weeks in Poland, whereas in the U.S. it took a full year to build a similar, complete cohort.